Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Increased globalization of the pharmaceutical market has facilitated the unobstructed and fast spread of poor-quality medicines. Poor-quality medicines include spurious/falsely-labeled/falsified/counterfeit drugs (those that are deliberately and fraudulently mislabeled with respect to content and/or origin), substandard drugs (legitimate drugs that do not meet their quality specifications), and degraded medicines (good quality pharmaceuticals that suffered from deterioration caused by improper storage or distribution). Consumption of poor-quality pharmaceuticals is likely to increase morbidity and mortality. Moreover, poor-quality drugs can also contribute to the development of resistance to anti-infective medicines and decrease the quality of health care received by patients. To assess the true prevalence of poor quality drugs, tiered technology approaches enabling the testing of drug samples collected at points of sale are required, thus ensuring public health standards. High throughput and high resolution ambient mass spectrometry techniques allow investigation of pharmaceuticals with minimal or no sample preparation, thus possessing capabilities to survey a large number of drug samples for their authenticity. © 2014 The Royal Society of Chemistry.

Original publication




Journal article



Publication Date





9 - 19